TMO - Quidel leads a slump in COVID-19 test makers

Quidel Corporation ([[QDEL]] -10.9%) has failed to meet the consensus revenue estimates in Q4 2020 despite the surging pandemic driving a ~80.6% YoY sequential growth in revenue from COVID-19 products.Today, the stock is leading a broader selloff among COVID-19 test makers after Evercore ISI analyst Vijay Kumar reportedly said ‘1Q could potentially be the peak testing Q’ in an email to Bloomberg.Late January, Raymond James upgraded Quidel to Outperform from Market Perform arguing that the company’s ‘core business is well positioned.’Related tickers: OPKO Health ([[OPK]] -7.6%), Meridian Bioscience ([[VIVO]] -10.1%), Hologic ([[HOLX]] -6.7%), OraSure Technologies ([[OSUR]] -9.2%), Fluidigm Corporation ([[FLDM]] -3.8%), ([[GNMK]] -5.0%), GenMark Diagnostics ([[PKI]] -3.3%), Bio-Rad Laboratories ([[BIO]] -2.0%), Becton, Dickinson ([[BDX]] -2.2%), Thermo Fisher Scientific ([[TMO]] -1.6%)

For further details see:

Quidel leads a slump in COVID-19 test makers